There is growing evidence of a preventive effect of Rituximab (RTX) in neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a first-line therapy or as a rescue … Lire la suite
OBJECTIVE: To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modifying therapy (DMT). CONCLUSION: This study provides level IV evidence that rituximab … Lire la suite
Auteurs : Hélène Zéphir, Raphaël Bernard-Valnet, Christine Lebrun, Olivier Outteryck, Bertrand Audoin, Bertrand Bourre, Sophie Pittion, et al. Télécharger la publication
Lire la suiteAuteurs : Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP. Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub … Lire la suite
